Real-world clinical efficacy of epidermal growth factor receptor inhibitors in patients with early-onset, metastatic colorectal cancer

January 17, 2024

Our summary

Colorectal cancer is on the rise among people aged under 50, contributing to a growing proportion of colorectal cancer cases. Current guidelines for treating colorectal cancer do not distinguish between those diagnosed before 50 (early-onset) and those diagnosed at 50 or later (late-onset). In light of this, there remains uncertainty about how well treatments work for patients with early-onset colorectal cancer.

Prior research suggests that response to EGFR inhibitors may differ between early and late-onset cases, especially for patients with specific characteristics like KRAS wild-type and left-sided metastatic cancer. 

This study aims to fill the knowledge gap by using real-world data to elucidate the comparative real-world effectiveness of EGFR inhibitors in patients with early-onset vs late-onset RAS/BRAF wild-type left-sided metastatic colorectal cancer in the United States (US).

Why this matters

This study is crucial as it explores survival outcomes among patients with early- and late-onset metastatic colorectal cancer in a real-world setting. The findings from this research highlights the need for identifying tailored therapeutic strategies based on the unique characteristics of different patient groups in the US and beyond.

Read the research